Healthcare providers across Canada will soon be able to capture adverse events in the Auxita platform through integration with MyMeds&Me’s pharmacovigilance SaaS platform, Reportum.®
This partnership integrates MyMeds&Me’s validated safety data capture solution into Auxita, enabling healthcare providers, patient support programs and pharmaceutical companies to capture and manage data more efficiently.
MyMeds&Me® is a global organization that provides an established end-to-end pharmacovigilance solution to simplify adverse event and product quality data capture. Its drug safety platform, Reportum, is used by pharmaceutical companies around the world to standardize data capture, streamline downstream processes and provide real-time access to complete, relevant safety information.
“Auxita is pleased to expand our service offering to enhance the management of safety data, captured at source from healthcare providers,” says Matt Cahill, CEO of Auxita. “Through our EMR and EHR-integrated platform, we provide an intuitive and standardized digital process to collect data and manage the flow of information throughout the patient journey. This partnership will offer patient support programs real-time access and enhanced visibility to key safety information.”
“Robust pharmacovigilance relies on a comprehensive body of complete, structured, and timely data. Therefore, it is critical that we make safety reporting really easy and intuitive for both physicians and patient support program staff whether in the office or out in the field” says Dr. Andrew Rut, CEO and founder of MyMeds&Me. “Our partnership with Auxita enables efficient capture of standardized information for our clients so they can accelerate safety insights.”
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritis
April 17th 2024Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.